Plomestane

Plomestane
Clinical data
Other names	MDL-18962; Propargylestrenedione; PED; 10-(2-Propyn-1-yl)estr-4-ene-3,17-dione; 10-Propargylestr-4-ene-3,17-dione
ATC code	None;
Identifiers
	IUPAC name 10H-(2-Propynyl)-estr-4-ene-3,17-dione;
CAS Number	77016-85-4;
PubChem CID	9904788;
ChemSpider	8080442;
UNII	FL3VS913TW;
CompTox Dashboard (EPA)	DTXSID601318490 ;
Chemical and physical data
Formula	C21H26O2
Molar mass	310.437 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C4\C=C3/[C@@](CC#C)([C@H]2CC[C@@]1(C(=O)CC[C@H]1[C@@H]2CC3)C)CC4;
	InChI InChI=1S/C21H26O2/c1-3-10-21-12-8-15(22)13-14(21)4-5-16-17-6-7-19(23)20(17,2)11-9-18(16)21/h1,13,16-18H,4-12H2,2H3/t16-,17-,18-,20-,21-/m0/s1; Key:JKPDEYAOCSQBSZ-OEUJLIAZSA-N;

Plomestane (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name; former developmental code name MDL-18962; also known as propargylestrenedione, PED) is a steroidal, irreversible aromatase inhibitor which was under development by Marion Merrell Dow/Hoechst Marion Russell (now Hoechst AG) as an antineoplastic agent for the treatment of breast cancer. It was found to be effective in preclinical studies and was also found to produce few adverse effects in human clinical trials, significantly reducing estrogen levels with a single administration. However, development of the drug for clinical use was halted due to "technical issues" and it was never marketed.

In addition to its activity as an aromatase inhibitor, plomestane has weak androgenic properties.